- Home
- BBN vs ABCL Comparison
BBN vs ABCL Comparison
Compare BBN & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BBN | ABCL |
|---|---|---|
| Founded | 1983 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BBN | ABCL |
|---|---|---|
| Price | $16.39 | $3.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 231.8K | ★ 3.1M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 6.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,325,000.00 |
| Revenue This Year | N/A | $25.45 |
| Revenue Next Year | N/A | $10.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 7.17 |
| 52 Week Low | $14.33 | $1.89 |
| 52 Week High | $18.36 | $6.52 |
Technical Indicators
Market Signals| Indicator | BBN | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 31.62 | 44.29 |
| Support Level | $16.49 | $3.32 |
| Resistance Level | $17.05 | $3.82 |
| Average True Range (ATR) | 0.20 | 0.19 |
| MACD | -0.08 | 0.06 |
| Stochastic Oscillator | 2.69 | 51.85 |
Price Performance
Historical ComparisonAbout BBN BlackRock Taxable Municipal Bond Trust of Beneficial Interest
BlackRock Taxable Municipal Bond Trust is a diversified, closed-end management investment company. Its investment objective is to seek high current income, with a secondary objective of capital appreciation.
About ABCL AbCellera Biologics Inc.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.